ReviewFrontiers in oncology2021
Clinical and Molecular Properties of Human Immunodeficiency Virus-Related Diffuse Large B-Cell Lymphoma.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical Characteristics and Prognostic Analysis of EBV-Positive HIV-Associated Diffuse Large B-Cell Lymphoma in China: A Retrospective Single-Center Study.Current oncology (Toronto, Ont.) · 2026Article
- Visual prognosis and survival outcomes in patients with ocular adnexal diffuse large B-cell lymphoma.International journal of ophthalmology · 2026Article
- HIV-driven tumor ecosystem: from chronic immune dysfunction to cancer evolution.Frontiers in microbiology · 2026Review
- The Characteristics of Peripheral Blood Lymphocyte Subsets in HIV-related Diffuse Large B-cell Lymphoma Patients and Their Impact on Treatment Efficacy.Current HIV research · 2026Article
- Emerging Roles of Fc Receptor-Like 1 in Immunotherapy of Diffuse Large B-Cell Lymphoma.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2025Article
- Pathological Mechanisms Involved in HIV-Associated Lymphomagenesis: Novel Targeted Therapeutic Approaches.Cells · 2025Review
- Serum β2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China.Scientific reports · 2025Article
- The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma.Journal of the National Cancer Center · 2025Article
- Acute myeloid leukemia following remission of AIDS-associated extra-nodal NK/T-cell lymphoma.Heliyon · 2024Article
- HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma.British journal of haematology · 2024Article
- HIV infection and ART exposure affect tumor TCR repertoire of diffuse large B cell lymphoma.JCI insight · 2024Article
- Article
- Transforming RNA-Seq gene expression to track cancer progression in the multi-stage early to advanced-stage cancer development.PloS one · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Hodgkin lymphoma is the most common malignancy affecting people living with HIV (PLWH). Among its several subtypes, diffuse large B-cell lymphoma (DLBCL) is an important manifestation within the HIV-infected compartment of the population. Since HIV is able to modulate B cells and promote lymphomagenesis through direct and indirect mechanisms, HIV-related DLBCL has specific characteristics. In this review, we address the clinical and molecular properties of DLBCL disease in the context of HIV infection, as well as the mechanisms by which HIV is able to modulate B lymphocytes and induce their transformation into lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.